1 day Ago By ABMN Staff
Sutro Biopharma ( NASDAQ:STRO – Get Free Report ) ‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $12.00 price objective on the stock.
HC Wainwright’s price objective would suggest a potential upside of 199.25% from the company’s previous close. Separately, Truist Financial dropped their target price on shares of Sutro Biopharma from $18.
00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.
com, the stock has an average rating of “Buy” and an average price target of $12.13. Read Our Latest Research Report on STRO Sutro Biopharma Stock Performance Sutro Biopharma ( NASDAQ:STRO – Get Free Report ) last released its quarterly earnings results on Tuesday, August 13th.
The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.
20. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.
06%. The firm had revenue of $25.71 million during the quarter, compared to the consensus estimate of $26.
28 million. On average, equities analysts predict that Sutro Biopharma will post -2.96 EPS for the current fiscal year.
Institutional Trading of Sutro Biopharma Hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC raised its holdings in Sutro Biopharma by 49.1% in the 2nd quarter.
ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $60,000. Lazard Asset Management LLC purchased a new position in shares of Sutro Biopharma during the 1st quarter worth approximately $92,000.
The Manufacturers Life Insurance Company increased its holdings in Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after purchasing an additional 7,082 shares during the last quarter.
Finally, Price T Rowe Associates Inc. MD raised its position in Sutro Biopharma by 24.8% in the first quarter.
Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after purchasing an additional 3,578 shares during the period. Hedge funds and other institutional investors own 96.
99% of the company’s stock. About Sutro Biopharma ( Get Free Report ) Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+.
Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. See Also Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
